Ming Q. Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ming Q. Wei has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Albert Sleiman Mellick
Griffith University
1 shared publication Asferd Mengesha
Maastro Lab, UNS50/23, University of Maastricht, Maastricht, The Netherlands
1 shared publicationBert Vogelstein
John Hopkins School of Medicine, Baltimore, MD, USA
1 shared publicationChun Li
Division of Molecular and Gene Therapies, Griffith Health Institute and School of Medical Science, Griffith University, Gold Coast, QLD 4222, Australia
1 shared publicationChun Xue Bai
Zhong Shan Hospital, Fudan University, Shanghai, PR China
1 shared publicationDavid Good
Division of Molecular Medicine and Gene Therapy, Griffith Institute for Health and Medical Research, G16, Gold Coast campus, Griffith University, Qld 4222, Australia
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2013, 1-11
The Mechanisms of Chansu in Inducing Efficient Apoptosis in Colon Cancer Cells
Chansu is one of the most widely used traditional Chinese medicines in China, Japan, and other Southeast Asian countries primarily for antipain, anti-inflammation, and recently anticancer. Over 10 recipes and remedies contained Chansu, which are easily available in pharmacies and hospitals, but the mechanisms of action were not clearly articulated. In the present study, Cinobufagin (CBF), the major compound of Chansu, was employed as a surrogate marker to determine its ability in inducing cancer cell death. As expected, CBF has significant cancer-killing capacity for a range of cancers, but such ability differs markedly. Colon and prostate cancers are more sensitive than skin and lung cancers. Interestingly, cancer cells die through apoptotic pathway either being biphasic caspase-3-dependent (HCT116) or independent (HT29). Multipathway analysis reveals that CBF-induced apoptosis is likely modulated by the hypoxia-inducing factor-1 alpha subunit (HIF-1α) as its inhibition was evidentin vitroandin vivo. Taken together, these results demonstrate that CBF is a potent apoptotic inducer with potential for further development as a novel and effective anticancer agent for a range of cancers, especially colon cancer.
- 1 January 2013
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2013, 1-11
Open AccessThe Mechanisms of Chansu in Inducing Efficient Apoptosis in Colon Cancer Cells
Chansu is one of the most widely used traditional Chinese medicines in China, Japan, and other Southeast Asian countries primarily for antipain, anti-inflammation, and recently anticancer. Over 10 recipes and remedies contained Chansu, which are easily available in pharmacies and hospitals, but the mechanisms of action were not clearly articulated. In the present study, Cinobufagin (CBF), the major compound of Chansu, was employed as a surrogate marker to determine its ability in inducing cancer cell death. As expected, CBF has significant cancer-killing capacity for a range of cancers, but such ability differs markedly. Colon and prostate cancers are more sensitive than skin and lung cancers. Interestingly, cancer cells die through apoptotic pathway either being biphasic caspase-3-dependent (HCT116) or independent (HT29). Multipathway analysis reveals that CBF-induced apoptosis is likely modulated by the hypoxia-inducing factor-1 alpha subunit (HIF-1α) as its inhibition was evidentin vitroandin vivo. Taken together, these results demonstrate that CBF is a potent apoptotic inducer with potential for further development as a novel and effective anticancer agent for a range of cancers, especially colon cancer.
- 1 January 2008
- Published by Elsevier in Cancer Letters
- Vol. 259 (1) , 16-27
Bacterial targeted tumour therapy-dawn of a new era
- 1 January 2008
- Published by Elsevier in Cancer Letters
- Vol. 259 (1) , 16-27
Bacterial targeted tumour therapy-dawn of a new era
- 1 February 2007
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (3) , 490-496
Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours
- 1 February 2007
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (3) , 490-496
Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours